PARKINSON'S DISEASE NEWS

19th May 2010 - New research

PROLONGED RELEASE ROPINIROLE CLINICAL TRIAL RESULTS

Movement Disorders [2010] 25 (7) : 927-931 (Hersh BP, Earl NL, Hauser RA, Stacy M.) Complete abstract

Movement Disorders [2010] 25 (7) : 858-866 (Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL; 228 Study Investigators) Complete abstract

Prolonged Release Ropinirole was found to have a positive effect on Parkinson's Disease symptoms two weeks after its use begins. Prolonged Release Ropinirole is a once a day dopamine agonist that is marketed as Requip XL. For more information go to Ropinirole. However, the  improvements it caused were minimal. PR Ropinirole improved "off time" but only by 42 minutes per day.  It increased "on time" without dyskinesia, but only by 24 minutes per day. Improvements were seen in Parkinson's Disease scores, but only slightly. Even these small improvements are achieved by also causing side effects.

In another study, Prolonged Release Ropinirole was found to delay the onset of dyskinesia when added to L-dopa when compared to increasing the L-dopa dosage. Otherwise there was no difference in Parkinson's Disease symptom scores. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported.  For more current news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports